Laboratory Methods in the Assessment of Hereditary Hemostatic Disorders.
Fibrinolytic system
Hemostasis
Hereditary bleeding disorders
Laboratory investigation
Journal
Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
pubmed:
16
8
2021
medline:
3
3
2022
entrez:
15
8
2021
Statut:
ppublish
Résumé
In patients presenting with a suspect hereditary bleeding disorder a detailed bleeding history is first obtained. Testing proceeds in a tiered manner with platelet count, platelet morphology, platelet histogram, PFA-100, fibrinogen, prothrombin time, and activated partial thromboplastin time. More detailed testing includes von Willebrand factor, individual clotting factor assays, and platelet function testing. Next, testing for a dysfibrinogenemia, FXIII, or a fibrinolytic defect is considered. Hemostatic abnormality is not demonstrated in a fraction of patients. An approach to management in these patients, such as desmopressin or antifibrinolytic therapy, may be required and empiric use of blood component therapy is discouraged.
Identifiants
pubmed: 34391602
pii: S0889-8588(21)00081-2
doi: 10.1016/j.hoc.2021.07.002
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1051-1068Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest T.A. Cheves-none; J.D. Sweeney-none; S. DeMarinis -none.